CPE | Erlotinib monotherapy | All | |
Patients | 11 | 11 | 22 |
Age, years | 60 (58–64) | 67 (62–68) | 64 (59–68) |
Males | 5 (45) | 5 (45) | 10 (45) |
Performance score | |||
0 | 8 (73) | 7 (64) | 15 (68) |
1 | 3 (27) | 4 (36) | 7 (32) |
Smoking | |||
Never-smoker | 6 (55) | 2 (18) | 8 (36) |
Former smoker | 5 (45) | 5 (45) | 10 (45) |
Current smoker | 0 (0) | 4 (36) | 4 (18) |
Pack-years | 14 (9–15) | 14 (6–19) | 14 (7–18) |
Stage IV | 11 (100) | 11 (100) | 22 (100) |
Nonsquamous | 11 (100) | 11 (100) | 22 (100) |
Type of EGFR mutation | |||
Exon 19 deletion | 7 (64) | 7 (64) | 14 (64) |
L858R | 2 (18) | 3 (27) | 5 (23) |
Other | 2 (18) | 1 (9) | 3 (13) |
Data are presented as n, median (interquartile range) or n (%). CPE: cisplatin-pemetrexed-erlotinib; EGFR: epidermal growth factor receptor.